Chengdu Institute of Biological Products Co., Ltd. (hereinafter referred to as "the Company") is a wholly-owned subsidiary of China Biotechnology Co., Ltd., a Fortune Global 500 enterprise managed by the State owned Assets Supervision and Administration Commission of the State Council and the largest pharmaceutical industry group in China. It is a national high-tech enterprise.

  The company is located in Jinjiang District, Chengdu City, Sichuan Province. As one of the important biological product production, research and development, and talent bases in China, since its establishment in 1958, the company has been committed to research in medical microbiology, immunology, and genetic engineering for a long time. It has developed and produced various preventive and therapeutic biological products, diagnostic products, gene recombination drugs, etc., providing safe and effective vaccines for the expansion of the national immunization program (EPI), and making important contributions to the prevention of infectious diseases. The company has been awarded the titles of Advanced Grassroots Party Organization for Striving for Excellence by the State owned Assets Supervision and Administration Commission of Sichuan Province for consecutive years, Top 20 Best Efficiency Enterprises in Sichuan Province's Pharmaceutical Manufacturing Industry, and Top 100 Enterprises in Chengdu. It has also been awarded titles such as Advanced Enterprise in Quality Management and Advanced Enterprise in Integrity and Law abiding in Sichuan Province.

  In recent years, under the guidance of the "international operation and technological innovation" strategy, the company has actively benchmarking with international advanced enterprises and implementing the "four modernizations" transformation of concept, management, quality, and hardware internationalization. In 2013, the company became the first domestic Japanese encephalitis vaccine to pass the pre certification of the World Health Organization (WHO). The company's 23 valent pneumococcal polysaccharide vaccine is the third global and the first domestic 23 valent pneumococcal vaccine product. In 2013, the first BCG vaccine for adjuvant treatment of bladder cancer in China was successfully industrialized in the company.